Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03205930Phase 1Unknown

Neo-MASCT Immunotherapy for Advanced NSCLC.

Role: collaborator

NCT02858232Phase 1Unknown

MASCT-I Treatment for Advanced Solid Tumor

Role: collaborator

NCT02844881Phase 1Unknown

Study of Apatinib and MASCT in Patients With Advanced Solid Tumors

Role: collaborator

All 3 trials loaded